Overview of Bispecific Engagers Administration Program

Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.

During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.

The oral KRAS G12D inhibitor VS-7375 elicited clinical responses across patients with KRAS G12D–mutant pancreatic, lung, and colorectal cancer.

ASH updates myelofibrosis care with expanded molecular testing, earlier transplant consultation, tailored JAK inhibitor use, anemia strategies, and aspirin guidance to reduce clot risk.

FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.

FDA accepts updated tab-cel BLA for EBV+ PTLD after transplant, adding ALLELE data; PDUFA decision set for March 31, 2027.

Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.

During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.